Recruiting

Testing combination treatment for advanced stomach cancer before surgery

Plain-English translation of NCT07277439 on ClinicalTrials.gov ↗ · Source last updated March 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a combination of three treatments for advanced stomach cancer before surgery: serplulimab (an immune-boosting medication), chemotherapy drugs, and radiation therapy. Some participants will also receive an additional immune-supporting medication called thymosin alpha 1 for 9 weeks. The study wants to see if this combination approach helps shrink tumors and improves survival after surgery.

Advanced stomach cancer is difficult to treat, and giving strong treatment before surgery may help destroy more cancer cells and improve the chances of successfully removing all the cancer. This trial is exploring whether adding immune-boosting medications to standard chemotherapy and radiation can make the treatment more effective.

Do you qualify?

You likely qualify if…

you are between 18 and 75 years old
you have been diagnosed with advanced adenocarcinoma (a type of cancer) at the junction where the stomach meets the esophagus
you are otherwise healthy enough to undergo major surgery
you have not received any previous cancer treatment, including chemotherapy, radiation, or immunotherapy
your blood work and organ function tests show you can safely tolerate these medications
you are able and willing to commit to the full treatment plan and follow-up care

You likely don't qualify if…

you have received any prior cancer treatment for this disease
you have serious heart, lung, liver, or kidney problems that would make treatment unsafe
you have a low blood cell count or blood clotting disorder
you are pregnant, breastfeeding, or unwilling to use reliable birth control during and after treatment
you have another active cancer or serious medical condition that would interfere with the study

What participation looks like

Over several months before your scheduled surgery, you will receive three cycles of treatment. Each cycle involves intravenous infusions of the medications, plus chemotherapy pills you take at home twice daily. Starting in the second cycle, you will also undergo radiation therapy to the tumor area, given 5 days a week for several weeks. Some participants will receive an additional immune-supporting medication as injections or infusions for 9 weeks. After completing all the treatment, you will have surgery to remove the cancer, followed by standard follow-up care and monitoring.

AI-generated summary from trial data · Jun 7, 2026 · Not medical advice

Trial locations(1 site)

China

First Affiliated Hospital of Nanjing Medical Unviersity, Nanjing, Jiangsu

Key details

Phase

Testing effectiveness

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Enrollment target

~48 participants

Started

December 2025

Primary completion

February 2027

Age range

18 Years – 75 Years

Last updated on clinicaltrials.gov in March 2026.

Contact the research team directly

Reach out to the team running this trial. Response times vary — some teams are faster than others.

Central contact

The First Affiliated Hospital with Nanjing Medical University

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.